Elicio Therapeutics, Inc.
About Elicio Therapeutics, Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $2.3M
- Net income
- -$39.6M
- Total assets
- $25.9M
- Market cap
- $253.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$37.7M
- Income tax
- $0
- Net income
- -$39.6M
- EPS (basic)
- $-2.58
- EPS (diluted)
- $-2.58
Balance sheet
- Total assets
- $25.9M
- Current assets
- $19.3M
- Total liabilities
- $24.2M
- Current liabilities
- $8.1M
- Shareholders’ equity
- $1.6M
Cash flow
- Operating cash flow
- -$37.0M
- Investing cash flow
- -$16.0K
- Financing cash flow
- $36.7M
- Net cash flow
- -$225.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $253.1M
- EPS (diluted)
- $-2.58
- Shares outstanding
- 17.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 2, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.6M in FY2022.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Elicio Therapeutics, Inc..
Write a review
News about Elicio Therapeutics, Inc.
News & sentiment via Polygon.io
